Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study

• DOI: 10.1007/s00228-011-1093-5
• Publication Date: 2011-07-06T13:34:37Z
• Authors: Trine Naalsund An...; Ingrid Eftedal; Pål Klepstad; Andrew Davies; Kristin Bjordal; Staffan Lundström; Stein Kaasa; Ola Dale
• Keywords: Oxymorphone; Brief Pain Inventory; Pharmacodynamics; Pediatric cancer

Opioids are recommended by the World Health Organization for moderate to severe cancer pain. Oxycodone is one of most commonly used opioids and metabolized in liver CYP3A4 CYP2D6 enzymes. The aim this cross-sectional study was assess relationship between oxycodone pharmacokinetics, pharmacodynamics genotypes "poor metaboliser" (PM), "extensive (EM) "ultra-rapid (URM) a cohort patients with pain.The were genotyped common variants serum concentrations metabolites determined. Pain assessed using Brief Inventory (BPI). EORTC QLQ-C30 symptoms tiredness nausea. Cognitive function Mini Mental State (MMS) examination. Associations examined analyses variance (ANOVA) covariance (ANCOVA), or ordinal logistic regressions without covariates.The sample consisted 27 PM, 413 EM (including heterozygotes) 10 URM. PM had lower oxymorphone noroxymorphone ratios than No differences URM pain intensity, nausea, cognitive found.CYP2D6 caused expected but they no pharmacodynamic consequence. did not influence control, adverse nausea sedation risk failure treated